Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. more
Time Frame | ALVO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.26% | -1.66% | 0.16% |
1-Month Return | -7.62% | -3.08% | 1% |
3-Month Return | 1.62% | -6.66% | 10.69% |
6-Month Return | -21.99% | -1.54% | 12.9% |
1-Year Return | 23.68% | 8.85% | 30.94% |
3-Year Return | 14.29% | 7.9% | 29.66% |
5-Year Return | 15.69% | 45.12% | 92.82% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.92M | 66.62M | 36.77M | 83.03M | 91.43M | [{"date":"2019-12-31","value":34.91,"profit":true},{"date":"2020-12-31","value":72.86,"profit":true},{"date":"2021-12-31","value":40.22,"profit":true},{"date":"2022-12-31","value":90.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | - | 64.09M | 160.86M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":39.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 31.92M | 66.62M | 36.77M | 18.93M | (69.42M) | [{"date":"2019-12-31","value":47.91,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":55.2,"profit":true},{"date":"2022-12-31","value":28.42,"profit":true},{"date":"2023-12-31","value":-104.21,"profit":false}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 22.80% | (75.93%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.8,"profit":true},{"date":"2023-12-31","value":-75.93,"profit":false}] |
Operating Expenses | 93.37M | 204.15M | 272.23M | 365.38M | 285.44M | [{"date":"2019-12-31","value":25.55,"profit":true},{"date":"2020-12-31","value":55.87,"profit":true},{"date":"2021-12-31","value":74.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.12,"profit":true}] |
Operating Income | (61.45M) | (137.54M) | (235.46M) | (346.44M) | (354.86M) | [{"date":"2019-12-31","value":-6144800000,"profit":false},{"date":"2020-12-31","value":-13753700000,"profit":false},{"date":"2021-12-31","value":-23545600000,"profit":false},{"date":"2022-12-31","value":-34644200000,"profit":false},{"date":"2023-12-31","value":-35486000000,"profit":false}] |
Total Non-Operating Income/Expense | (244.77M) | (254.75M) | (28.28M) | (295.73M) | (426.19M) | [{"date":"2019-12-31","value":-24477200000,"profit":false},{"date":"2020-12-31","value":-25474600000,"profit":false},{"date":"2021-12-31","value":-2828000000,"profit":false},{"date":"2022-12-31","value":-29573100000,"profit":false},{"date":"2023-12-31","value":-42619000000,"profit":false}] |
Pre-Tax Income | (209.38M) | (291.77M) | (149.20M) | (551.65M) | (651.05M) | [{"date":"2019-12-31","value":-20938500000,"profit":false},{"date":"2020-12-31","value":-29177000000,"profit":false},{"date":"2021-12-31","value":-14919800000,"profit":false},{"date":"2022-12-31","value":-55164700000,"profit":false},{"date":"2023-12-31","value":-65104900000,"profit":false}] |
Income Taxes | 491.00K | (121.73M) | (47.69M) | (38.07M) | (99.32M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-24791.45,"profit":false},{"date":"2021-12-31","value":-9713.65,"profit":false},{"date":"2022-12-31","value":-7752.95,"profit":false},{"date":"2023-12-31","value":-20227.7,"profit":false}] |
Income After Taxes | (209.88M) | (170.04M) | (101.50M) | (513.58M) | (551.73M) | [{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}] |
Income From Continuous Operations | (209.88M) | (170.04M) | (101.50M) | (513.58M) | (551.73M) | [{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (209.88M) | (170.04M) | (101.50M) | (513.58M) | (551.73M) | [{"date":"2019-12-31","value":-20987600000,"profit":false},{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false}] |
EPS (Diluted) | - | (0.30) | 0.13 | (5.53) | (3.42) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-231.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4330.67,"profit":false},{"date":"2023-12-31","value":-2676.06,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALVO | |
---|---|
Cash Ratio | 0.74 |
Current Ratio | 2.69 |
Quick Ratio | 1.92 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALVO | |
---|---|
ROA (LTM) | -7.61% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALVO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.28 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALVO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 11.16 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 11.50 |
EV/Ebitda | NM |
Alvotech (ALVO) share price today is $11.375
Yes, Indians can buy shares of Alvotech (ALVO) on Vested. To buy Alvotech from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alvotech (ALVO) via the Vested app. You can start investing in Alvotech (ALVO) with a minimum investment of $1.
You can invest in shares of Alvotech (ALVO) via Vested in three simple steps:
The 52-week high price of Alvotech (ALVO) is $18. The 52-week low price of Alvotech (ALVO) is $9.15.
The price-to-earnings (P/E) ratio of Alvotech (ALVO) is
The price-to-book (P/B) ratio of Alvotech (ALVO) is 0.00
The dividend yield of Alvotech (ALVO) is 0.00%
The market capitalization of Alvotech (ALVO) is $3.45B
The stock symbol (or ticker) of Alvotech is ALVO